Combination Bicalutamide, Everolimus May be Efficacious in Prostate Cancer

Share this content:
Combination bicalutamide and everolimus may be efficacious in men with bicalutamide-naïve castration-resistant prostate cancer.
Combination bicalutamide and everolimus may be efficacious in men with bicalutamide-naïve castration-resistant prostate cancer.

Combination bicalutamide and everolimus may be efficacious in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC), according to a study published in Cancer.1

However, these patients may be at high risk of experiencing everolimus-related toxicity.

Researchers led by Helen Chow, MD, of the University of California Davis in Sacramento looked at 24 patients with a mean age of 71.1 years who had serum testosterone levels less than 50 ng/dL and no prior bicalutamide or everolimus use. Patients were given oral bicalutamide 50 mg and oral everolimus 10 mg once daily, during each 4-week cycle.

Primary endpoint was prostate-specific antigen (PSA) response from baseline.

RELATED: Open, Robot-assisted Radical Prostatectomy Linked With Favorable Outcomes

Among the observed patients, 18 were found have a PSA response, whereas 15 had a PSA decrease of at least 50%. Median overall survival was found to be 28 months, and 14 patients developed grade 3 or grade 4 adverse events that were attributable to treatment.

Reference

  1. Chow H, Ghosh PM, deVere White R, et al. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer [published online ahead of print March 28, 2016]. Cancer. doi: 10.1002/cncr.29927.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs